BioLife Solutions (BLFS) Expected to Release Quarterly Earnings on Thursday

BioLife Solutions (NASDAQ:BLFS - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $22.22 million for the quarter. BioLife Solutions has set its FY 2025 guidance at EPS.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the previous year, the business posted ($0.21) EPS. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Stock Down 3.6 %

Shares of NASDAQ BLFS traded down $0.88 during midday trading on Tuesday, reaching $23.33. 226,537 shares of the company's stock traded hands, compared to its average volume of 377,115. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -22.07 and a beta of 1.93. The stock's 50 day simple moving average is $24.00 and its 200-day simple moving average is $25.32. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a one year low of $17.15 and a one year high of $29.55.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BLFS. StockNews.com lowered BioLife Solutions from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. HC Wainwright boosted their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Finally, Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat, BioLife Solutions currently has an average rating of "Moderate Buy" and an average price target of $31.17.

Insiders Place Their Bets

In related news, EVP Aby J. Mathew sold 1,597 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $39,925.00. Following the sale, the executive vice president now directly owns 260,601 shares of the company's stock, valued at $6,515,025. This trade represents a 0.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Troy Wichterman sold 4,151 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $103,775.00. Following the completion of the transaction, the chief financial officer now directly owns 116,809 shares of the company's stock, valued at $2,920,225. The trade was a 3.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,127 shares of company stock valued at $1,676,533. Company insiders own 2.20% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.